These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16515287)

  • 1. [The (new) definition of compliance].
    Arolt V
    Krankenpfl J; 2005; 43(7-10):214-5. PubMed ID: 16515287
    [No Abstract]   [Full Text] [Related]  

  • 2. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
    Naber D; Lambert M; Karow A
    Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Current status of recommendations for treatment with an APAP].
    Buis C; Gourion D; Vaiva G
    Encephale; 2009 Jan; Suppl 3():S91-5. PubMed ID: 19268185
    [No Abstract]   [Full Text] [Related]  

  • 4. Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission.
    Yen CF; Cheng CP; Huang CF; Yen JY; Ko CH; Chen CS
    Bipolar Disord; 2008 Jul; 10(5):617-24. PubMed ID: 18657246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Letter to the editor: on the articles by Klimitz H. "Psychoeducation in schizophrenic disorders--psychotherapy or 'infiltration'?" and Bäuml J. "Psychoeducation from a psychiatric-psychotherapeutic point of view". Psychiat Prax 2006; 33: 372-382 ].
    Böhme F
    Psychiatr Prax; 2007 Mar; 34(2):101-2. PubMed ID: 17390267
    [No Abstract]   [Full Text] [Related]  

  • 6. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications for the pharmacotherapy of schizophrenia.
    Rep Group Adv Psychiatry (1984); 1992; (134):35-58. PubMed ID: 1348372
    [No Abstract]   [Full Text] [Related]  

  • 8. [CUtLASS 1 - Increasing disillusion about 2nd generation neuroleptics].
    Steinert T
    Psychiatr Prax; 2007 Jul; 34(5):255-7. PubMed ID: 17607643
    [No Abstract]   [Full Text] [Related]  

  • 9. Preface: treatment optimization in schizophrenia through active patient management - proceedings from two European consensus meetings.
    Leucht S; van Os J
    Acta Psychiatr Scand Suppl; 2009; (438):5-6. PubMed ID: 19132960
    [No Abstract]   [Full Text] [Related]  

  • 10. Factors which can make patients difficult to treat.
    Kane JM
    Br J Psychiatry Suppl; 1996 Dec; (31):10-4. PubMed ID: 8968650
    [No Abstract]   [Full Text] [Related]  

  • 11. [Combining effectiveness and tolerance].
    Krankenpfl J; 2005; 43(1-3):26-7. PubMed ID: 15912821
    [No Abstract]   [Full Text] [Related]  

  • 12. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
    Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
    J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia.
    Perez V; Cañas F; Tafalla M;
    Int Clin Psychopharmacol; 2008 May; 23(3):138-49. PubMed ID: 18408528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
    Lee KU; Jeon YW; Lee HK; Jun TY
    Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scale for measuring self-recoverability in daily life for people with schizophrenia.
    Takamatsu T; Hashimoto T; Taira M; Fukutake M; Maeda K
    Psychiatry Clin Neurosci; 2009 Jun; 63(3):277-82. PubMed ID: 19566757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Co-enaesthetic schizophrenia. Case studies of illness perception and compliance].
    Schmoll D
    Fortschr Neurol Psychiatr; 1994 Oct; 62(10):372-8. PubMed ID: 8001893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negative symptoms of schizophrenia: a problem that will not go away.
    Stahl SM; Buckley PF
    Acta Psychiatr Scand; 2007 Jan; 115(1):4-11. PubMed ID: 17201860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release.
    Figueroa C; Brecher M; Hamer-Maansson JE; Winter H
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):199-204. PubMed ID: 18948162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep.
    Endicott J; Paulsson B; Gustafsson U; Schiöler H; Hassan M
    J Affect Disord; 2008 Dec; 111(2-3):306-19. PubMed ID: 18774180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ["Higher outcomes"--optimizing therapy of schizophrenia].
    Rüther E
    Krankenpfl J; 2004; 42(5-6):151. PubMed ID: 15527215
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.